Investors Menu
Tilray, Inc. Reports 2020 Full Fiscal Year and Fourth Quarter Results
Revenue Increased 26% to $210.5 Million in 2020 Compared to Prior Year Net Loss $(3.0) Million in Q4 2020 Versus Net Loss $(219.8) Million in Q4 2019 Achieved Adjusted EBITDA Goal With $2.2 Million in Q4 2020 Combination with Aphria Inc. Expected to Close in Q2 2021 to Create the World’s Largest
February 17, 2021
Tilray® Exports First Shipment of Medical Cannabis to Spain
Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis Tilray medical cannabis will now be available in 17 countries around the world NANAIMO, British Columbia --(BUSINESS WIRE)--Feb. 4, 2021-- Tilray, Inc.
February 4, 2021